Home > Research > Publications & Outputs > Plasma neurofilament light chain

Links

Text available via DOI:

View graph of relations

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients

Research output: Contribution to journalJournal article

Published

Standard

Plasma neurofilament light chain : A potential prognostic biomarker of dementia in adult Down syndrome patients. / Shinomoto, Makiko; Kasai, Takashi; Tatebe, Harutsugu; Kondo, Masaki; Ohmichi, Takuma; Morimoto, Masafumi; Chiyonobu, Tomohiro; Terada, Naoto; Allsop, David; Yokota, Isao; Mizuno, Toshiki; Tokuda, Takahiko.

In: PLoS ONE, Vol. 14, No. 4, e0211575, 05.04.2019.

Research output: Contribution to journalJournal article

Harvard

Shinomoto, M, Kasai, T, Tatebe, H, Kondo, M, Ohmichi, T, Morimoto, M, Chiyonobu, T, Terada, N, Allsop, D, Yokota, I, Mizuno, T & Tokuda, T 2019, 'Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients', PLoS ONE, vol. 14, no. 4, e0211575. https://doi.org/10.1371/journal.pone.0211575

APA

Shinomoto, M., Kasai, T., Tatebe, H., Kondo, M., Ohmichi, T., Morimoto, M., ... Tokuda, T. (2019). Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PLoS ONE, 14(4), [e0211575]. https://doi.org/10.1371/journal.pone.0211575

Vancouver

Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M et al. Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PLoS ONE. 2019 Apr 5;14(4). e0211575. https://doi.org/10.1371/journal.pone.0211575

Author

Shinomoto, Makiko ; Kasai, Takashi ; Tatebe, Harutsugu ; Kondo, Masaki ; Ohmichi, Takuma ; Morimoto, Masafumi ; Chiyonobu, Tomohiro ; Terada, Naoto ; Allsop, David ; Yokota, Isao ; Mizuno, Toshiki ; Tokuda, Takahiko. / Plasma neurofilament light chain : A potential prognostic biomarker of dementia in adult Down syndrome patients. In: PLoS ONE. 2019 ; Vol. 14, No. 4.

Bibtex

@article{77154dfa63be4c71b506fba11e1d7c48,
title = "Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients",
abstract = "People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.",
author = "Makiko Shinomoto and Takashi Kasai and Harutsugu Tatebe and Masaki Kondo and Takuma Ohmichi and Masafumi Morimoto and Tomohiro Chiyonobu and Naoto Terada and David Allsop and Isao Yokota and Toshiki Mizuno and Takahiko Tokuda",
year = "2019",
month = "4",
day = "5",
doi = "10.1371/journal.pone.0211575",
language = "English",
volume = "14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

RIS

TY - JOUR

T1 - Plasma neurofilament light chain

T2 - A potential prognostic biomarker of dementia in adult Down syndrome patients

AU - Shinomoto, Makiko

AU - Kasai, Takashi

AU - Tatebe, Harutsugu

AU - Kondo, Masaki

AU - Ohmichi, Takuma

AU - Morimoto, Masafumi

AU - Chiyonobu, Tomohiro

AU - Terada, Naoto

AU - Allsop, David

AU - Yokota, Isao

AU - Mizuno, Toshiki

AU - Tokuda, Takahiko

PY - 2019/4/5

Y1 - 2019/4/5

N2 - People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.

AB - People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.

U2 - 10.1371/journal.pone.0211575

DO - 10.1371/journal.pone.0211575

M3 - Journal article

C2 - 30951523

VL - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 4

M1 - e0211575

ER -